Diverse mechanisms of antiepileptic drugs in the development pipeline

Epilepsy Research

Volumn 69, Issue 3, 2006, Pages 273-294

  Rogawski, Michael A ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Antiepileptic drug; Drug discovery; Epilepsy models; Kindling model; Maximal electroshock test; Pentylenetetrazol test

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ANTICONVULSIVE AGENT; BENZANILIDE; BIA 2093; BRIVARACETAM; CARBAMAZEPINE; CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; CARBAMIC ACID DERIVATIVE; DIAZEPAM; DIISOPROPYL ACETAMIDE; ELB 139; ETIRACETAM; FELBAMATE; FLUOROFELBAMATE; GANAXOLONE; HARKOSERIDE; ICA 27243; ISOVALERAMIDE; LICARBAZEPINE; NS 1209; OXCARBAZEPINE; PROPYLISOPROPYL ACETAMIDE; RETIGABINE; RUFINAMIDE; RWJ 51204; SELETRACETAM; TALAMPANEL; TPA 023; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALNOCTAMIDE; VALPROIC ACID; VALPROMIDE; VALROCEMIDE;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG STRUCTURE; EMBRYOTOXICITY; EPILEPSY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICONVULSANTS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33747049831     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.02.004     Document Type: Review

References (166)

1. Abou-Khalil B., Porter R.J., and Nohria V. Safety and tolerability of different titration rates of the novel AED retigabine. Epilepsia 45 Suppl. 7 (2004) (2.356)
2. Almeida L., Falcao A., Maia J., Mazur D., Gellert M., and Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J. Clin. Pharmacol. 45 (2005) 1062-1066
3. Ambrósio A.F., Silva A.P., Malva J.O., Soares-da-Silva P., Carvalho A.P., and Carvalho C.M. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem. Pharmacol. 61 (2001) 1271-1275
4. Andrási F. Talampanel. Drugs Fut. 26 (2001) 754-756
5. Asano T., Mori T., Shimoda T., Shinagawa R., Satoh S., Yada N., Katsumata S., Matsuda S., Kagamiishi Y., and Tateishi N. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 127-142
6. A receptors, is a non-sedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther. 316 (2006) 410-422
7. Barel S., Yagen B., Schurig V., Soback S., Pisani F., Perucca E., and Bialer M. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin. Pharmacol. Ther. 61 (1997) 442-449
8. Barton M.E., Klein B.D., Wolf H.H., and White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47 (2001) 217-227
9. Barton M.E., Peters S.C., and Shannon H.E. Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res. 56 (2003) 17-26
10. Béguin C., Andurkar S.V., Jin A.Y., Stables J.P., Weaver D.F., and Kohn H. Functionalized amido ketones: new anticonvulsant agents. Bioorg. Med. Chem. 11 (2003) 4275-4285
11. Béguin C., LeTiran A., Stables J.P., Voyksner R.D., and Kohn H. N-Substituted amino acid N'-benzylamides: synthesis, anticonvulsant, and metabolic activities. Bioorg. Med. Chem. 12 (2004) 3079-3096
12. Benes J., Parada A., Figueiredo A.A., Alves P.C., Freitas A.P., Learmonth D.A., Cunha R.A., Garrett J., and Soares-da-Silva P. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J. Med. Chem. 42 (1999) 2582-2587
13. Bialer M. Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20 (1991) 114-122
14. Bialer M., Haj-Yehia A., Barzaghi N., Pisani F., and Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur. J. Clin. Pharmacol. 38 (1990) 289-291
15. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 43 (2001) 11-58
16. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., and Tomson T. Progress report on new anti epileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61 (2004) 1-48
17. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., Mikkelsen J.D., and Blackburn-Munro R.E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 11 (2005) 1-20
18. Blotnick S., Bergman F., and Bialer M. Disposition of valpromide, valproic acid and valnoctamide in the brain, liver, plasma and urine of rats. Drug Metab. Dispos. 24 (1996) 560-564
19. Bonifácio M.J., Sheridan R.D., Parada A., Cunha R.A., Patmore L., and Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 42 (2001) 600-608
20. Carter R.B., Wood P.L., Wieland S., Hawkinson J.E., Belelli D., Lambert J.J., White H.S., Wolf H.H., Mirsadeghi S., Tahir S.H., Bolger M.B., Lan N.C., and Gee K.W. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acidA receptor. J. Pharmacol. Exp. Ther. 280 (1997) 1284-1295
21. Chappell A.S., Sander J.W., Brodie M.J., Chadwick D., Lledo A., Zhang D., Bjerke J., Kiesler G.M., and Arroyo S. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58 (2002) 1680-1682
22. Choi D., Stables J.P., and Kohn H. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem. 39 (1996) 1907-1916
23. Choi, Y.M., Kim, M.W., Park, J., 1997. Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol. U.S. Patent 5,698,588, December 16, 1997.
24. Choi, Y.M., Kim, M.W., Park. J., 2000. Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol. U.S. Patent 6,103,759, August 15, 2000.
25. Conley J.D., and Kohn H. Functionalized dl-amino acid derivatives potent new agents for the treatment of epilepsy. J. Med. Chem. 30 (1987) 567-574
26. Cortes S., Liao Z.K., Watson D., and Kohn H. Effect of structural modification of the hydantoin ring on anticonvulsant activity. J. Med. Chem. 28 (1985) 601-606
27. Costa E., and Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol. Sci. 17 (1996) 192-200
28. Crestani F., Martin J.R., Möhler H., and Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br. J. Pharmacol. 131 (2000) 1251-1254
29. Danielsson I., Su K., Kauer L., Barnette L., Reeves-Tyer P., Kelley K., Theodore W.H., Wassermann E., and Rogawski M.A. Talampanel and human cortical excitability: EEG and TMS. Epilepsia 45 Suppl. 7 (2004) 120 (1.314)
30. de Paulis T. ONO-2506. Curr. Opin. Investig. Drugs 4 (2003) 863-867
31. Delmas P., and Brown D.A. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat. Rev. Neurosci. 6 (2005) 850-862
32. Depoortere H., Zivkovic B., Lloyd K.G., Sanger D.J., Perrault G., Langer S.Z., and Bartholini G. Zolpidem, a novel nonbenzodiazepine hypnotic I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther. 237 (1986) 649-658
33. Donevan S.D., and Rogawski M.A. GYKI 52466 a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10 (1993) 51-59
34. Dost, R., Langen, B., Rundfeldt, C., 2005. The α-3 subunit selective benzodiazepine agonist ELB139 does not induce tolerance in animal models for anxiety and epilepsy. Soc. Neurosci. Abst., Program No. 678.1.
35. Dubinsky B., Vaidya A.H., Rosenthal D.I., Hochman C., Crooke J.J., DeLuca S., DeVine A., Cheo-Isaacs C.T., Carter A.R., Jordan A.D., Reitz A.B., and Shank R.P. 5-Ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]p yridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J. Pharmacol. Exp. Ther. 303 (2002) 777-790
36. Eadie M.J. Could valerian have been the first anticonvulsant?. Epilepsia 45 (2004) 1338-1343
37. Faigle J.W., and Menge G.P. Metabolic characteristics of oxcarbazepine and their clinical significance: comparison with carbamazepine. Behav. Neurol. 3 suppl 1 (1990) 21-30
38. A receptors. Nat. Rev. Neurosci. 6 (2005) 215-229
39. Francois J., Ferrandon A., Koning E., and Nehlig A. A new drug RWJ 333369 protects limbic areas in the lithium-pilocarpine model (li-pilo) of epilepsy and delays or prevents the occurrence of spontaneous seizures. Epilepsia 46 Suppl. 8 (2005) 269-270 (C.04)
40. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22 (1995) 207-213
41. Gower A.J., Noyer M., Verloes R., Gobert J., and Wulfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222 (1992) 193-203
42. Grabenstatter H.L., and Dudek F.E. The use of chronic models in antiepileptic drug discovery: the effect of RWJ-333369 on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 45 Suppl. 7 (2004) 197 (2.016)
43. A receptor. Curr. Top. Med. Chem. 2 (2002) 887-902
44. Harty T.P., and Rogawski M.A. Felbamate block of recombinant N-methyl-d-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 39 (2000) 47-55
45. Herzog A.G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 45 (1995) 1660-1662
46. Holmes G.L. Carbamazepine adverse effects. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott-Raven, Philadelphia 284-297
47. Hovinga C.A. SPM-927 (Schwarz Pharma). IDrugs 6 (2003) 479-485
48. Hovinga C.A. Valrocemide (Teva/Acorda). Curr. Opin. Investig. Drugs 5 (2004) 101-106
49. Isoherranen N., White H.S., Klein B.D., Roeder M., Woodhead J.H., Schurig V., Yagen B., and Bialer M. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R 3S)-valnoctamide in rodent models of epilepsy. Pharm. Res. 20 (2003) 1293-1301
50. Isoherranen N., Woodhead J.H., White H.S., and Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia 42 (2001) 831-836
51. Isoherranen N., Yagen B., and Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?. Curr. Opin. Neurol. 16 (2003) 203-211
52. Isoherranen N., Yagen B., Woodhead J.H., Spiegelstein O., Blotnik S., Wilcox K.S., Finnell R.H., Bennett G.D., White H.S., and Bialer M. Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. Br. J. Pharmacol. 138 (2003) 602-613
53. 2+ regulators in neurotransmitter release. Neuron 24 (1999) 1003-1016
54. Jentsch T.J. Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev. Neurosci. 1 (2000) 21-30
55. Johnstone T.B., Hogenkamp D.J., Coyne L., Su J., Halliwell R.F., Tran M.B., Yoshimura R.F., Li W.Y., Wang J., and Gee K.W. Modifying quinolone antibiotics yields new anxiolytics. Nat. Med. 10 (2004) 31-32
56. Kaminski R.M., Livingood M.R., and Rogawski M.A. Allopregnanolone analogs that positively modulate GAB A receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 45 (2004) 864-867
57. Karolchyk M.A., and Schmidt D. Drugs in development rufinamide. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott-Raven, Philadelphia 906-912
58. Kasteleijn-Nolst Trenitè D.G., Parain D., Masnou P., Genton P., Steinhoff B.J., and Hirsch E. Proof of principle in the new AED UCB 34714 Use of the photosensitivity model. Epilepsia 45 Suppl. 7 (2004) 309 (2.346)
59. Kenda B.M., Matagne A.C., Talaga P.E., Pasau P.M., Differding E., Lallemand B.I., Frycia A.M., Moureau F.G., Klitgaard H.V., Gillard M.R., Fuks B., and Michel P. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem. 47 (2004) 530-549
60. Kleckner N.W., Glazewski J.C., Chen C.C., and Moscrip T.D. Subtype-selective antagonism of N-methyl-d-aspartate receptors by felbamate: insights into the mechanism of action. J. Pharmacol. Exp. Ther. 289 (1999) 886-894
61. Kleckner N.W., Glazewski J.C., Chen C.C., and Moscrip T.D. Subtype-selective antagonism of N-methyl-d-aspartate receptors by felbamate: insights into the mechanism of action. J. Pharmacol. Exp. Ther. 289 (1999) 886-894
62. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 42 Suppl. 4 (1999) 13-18
63. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353 (1998) 191-206
64. Kokate T.G., Banks M.K., Magee T., Yamaguchi S., and Rogawski M.A. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J. Pharmacol. Exp. Ther. 288 (1999) 679-684
65. Kokate T.G., Cohen A.L., Karp E., and Rogawski M.A. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 35 (1996) 1049-1056
66. Kokate T.G., Svensson B.E., and Rogawski M.A. Anticonvulsant activity of neurosteroids: correlation with γ-aminobutyric acid-evoked chloride current potentiation. J. Pharmacol. Exp. Ther. 270 (1994) 1223-1229
67. Kokate T.G., Yamaguchi S., Pannell L.K., Rajamani U., Carroll D.M., Grossman A.B., and Rogawski M.A. Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice. J. Pharmacol. Exp. Ther. 287 (1998) 553-558
68. A receptor α1 subunit knockout mice. J. Pharmacol. Exp. Ther. 302 (2002) 1037-1045
69. A) receptor. J. Pharmacol. Exp. Ther. 277 (1996) 1784-1792
70. Kuo C.C., Lin B.J., Chang H.R., and Hsieh C.P. Use-dependent inhibition of the N-methyl-d-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels. Mol. Pharmacol. 65 (2004) 370-380
71. A receptors by endogenous and synthetic neuroactive steroids. Brain Res. Brain Res. Rev. 37 (2001) 68-80
72. Langan Y.M., Lucas R., Jewell H., Toublanc N., Schaefer H., Sander J.W., and Patsalos P.N. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 44 (2003) 46-53
73. A receptor. J. Pharmacol. Exp. Ther. 314 (2005) 717-724
74. Langen, B., Rundfeldt, C., Dost, R., Luddens, H., Rabe, H., 2004. Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha3 subunit of the benzodiazepine receptor. U.S. Patent Application 20,050,032,863.
75. Lees G., Stohr T., and Errington A.C. Stereoselective effects of the novel anti con vulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro. Neuropharmacology 50 (2006) 98-110
76. Löscher W. Valproic acid mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott-Raven, Philadelphia 768-779
77. Löscher W., and Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232 (1993) 147-158
78. Löscher W., and Honack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Br. J. Pharmacol. 113 (1994) 1349-1357
79. Löscher W., Honack D., and Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 284 (1998) 474-479
80. Löscher W., and Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid anticonvulsant and toxic potencies in mice. Neuropharmacology 24 (1985) 427-435
81. Löscher W., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs IV. Protective indices. Epilepsy Res. 9 (1991) 1-10
82. Löscher W., and Rogawski M.A. Epilepsy. In: Lodge D., Danysz W., and Parsons C.G. (Eds). Ionotropic Glutamate Receptors as Therapeutic Targets (2002), F.P. Graham Publishing Co., Johnson City, TN 91-132
83. Löscher W., Rundfeldt C., and Honack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 5 (1993) 1545-1550
84. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
85. Main M.J., Cryan J.E., Dupere J.R., Cox B., Clare J.J., and Burbidge S.A. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. 58 (2000) 253-262
86. Marescaux C., Vergnes M., and Depaulis A. Genetic absence epilepsy in rats from Strasbourg-a review. J. Neural. Transm. Suppl. 35 (1992) 37-69
87. McAuley J.W., Moore J.L., Reeves A.L., Flyak J., Monaghan E.P., and Data J. A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: clinical experience in two patients. Epilepsia 42 Suppl. 7 (2001) 85
88. A receptor α1 subtype. Nat. Neurosci. 3 (2000) 587-592
89. McLean M.J., Schmutz M., Pozza M., and Wamil A. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia 46 Suppl. 8 (2005) 296 (3.061)
90. A receptor complex for the treatment of epilepsy. Expert Opin. Investig. Drugs 8 (1999) 1663-1671
91. Nau H., and Löscher W. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam. Appl. Toxicol. 6 (1986) 669-676
92. Nehlig A., Rigoulot M.-A., and Boehrer A. A new drug, RWJ 333369 displays potent antiepileptic properties in genetic models of absence and audiogenic epilepsy. Epilepsia 46 Suppl. 8 (2005) 215 (2.368)
93. Nielsen E.Ø., Varming T., Mathiesen C., Jensen L.H., Moller A., Gouliaev A.H., Watjen F., and Drejer J. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. J. Pharmacol. Exp. Ther. 289 (1999) 1492-1501
94. A receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J. Neurosci. 18 (1998) 1693-1703
95. Otto J.F., Kimball M.M., and Wilcox K.S. Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol. Pharmacol. 61 (2002) 921-927
96. Parada A., and Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem. Int. 40 (2002) 435-440
97. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
98. Petersen E.N. DMCM: a potent convulsive benzodiazepine receptor ligand. Eur. J. Pharmacol. 94 (1983) 117-124
99. Pisani F., Fazio A., Artesi C., Oteri G., Spina E., Tomson T., and Perucca E. Impairment of carbamazepine-10,11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. Br. J. Clin. Pharmacol. 34 (1992) 85-87
100. Pisani F., Haj-Yehia A., Fazio A., Artesi C., Oteri G., Perucca E., Kroetz D.L., Levy R.H., and Bialer M. Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia 34 (1993) 954-959
101. Pitkänen A. Drug-mediated neuroprotection and antiepileptogenesis: animal data. Neurology 59 9 Suppl. 5 (2002) S27-S33
102. Pitkänen A., Kharatishvili I., Narkilahti S., Lukasiuk K., and Nissinen J. Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res. 63 (2005) 27-42
103. Pugliese A.M., Passani M.B., Pepeu G., and Corradetti R. Felbamate decreases synaptic transmission in the CA1 region of rat hippocampal slices. J. Pharmacol. Exp. Ther. 279 (1996) 1100-1108
104. Radatz M., Ehlers K., Yagen B., Bialer M., and Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res. 30 (1998) 41-48
105. Reddy D.S., Castaneda D.C., O'Malley B.W., and Rogawski M.A. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J. Pharmacol. Exp. Ther. 310 (2004) 230-239
106. Reddy D.S., and Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. 295 (2000) 1241-1248
107. Reddy D.S., and Rogawski M.A. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J. Pharmacol. Exp. Ther. 294 (2000) 909-915
108. Reddy D.S., and Rogawski M.A. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 42 (2001) 337-344
109. A receptor function and seizure susceptibility. J. Neurosci. 22 (2002) 3795-3805
110. A receptors. Ann. Neurol. 35 (1994) 229-234
111. Rigdon, G.C., Roeloffs, R., Wickenden, A.D., McNaughton-Smith, G., Jones, L., Harrison, W., Ghodadra, N., McNamara, J.O., 2005. In vivo profile of ICA-27243, a potent and selective KCNQ2/3 activator in rodent anticonvulsant models. Soc. Neurosci. Abst. Prog. No. 153.15.
112. Rogawski M.A. Mechanism-specific pathways for new antiepileptic drug discovery. In: French J., Leppik I., and Dichter M.A. (Eds). Advances in Neurology vol. 76 (1998), Lippincott-Raven Publishers, Philadelphia 11-27
113. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14 (1993) 325-331
114. Rogawski M.A. Epilepsy. In: Pullan L., and Patel J. (Eds). Neurotherapeutics: Emerging Strategies (1996), Humana Press, Totowa, NJ 193-273
115. + channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. 23 (2000) 393-398
116. Rogawski M.A. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res. 68 (2006) 22-28
117. Rogawski M.A., and Donevan S.D. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv. Neurol. 79 (1999) 947-963
118. Rogawski M.A., Kurzman P.S., Yamaguchi S.I., and Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 40 (2001) 28-35
119. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (2004) 553-564
120. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10 (2004) 685-692
121. Rogawski M.A., and Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42 (1990) 223-286
122. Rogawski M.A., and Reddy D.S. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho J.M., Sankar R., and Cavazos J. (Eds). Epilepsy: Scientific Foundations of Clinical Practice (2004), Marcel Dekker, New York 319-355
123. Rogawski, M.A., Taylor, C.P., 2006. Calcium channel α2-δ subunit, a new antiepileptic drug target. Epilepsy Res., in press.
124. Rostock A., Tober C., Rundfeldt C., Bartsch R., Engel J., Polymeropoulos E.E., Kutscher B., Loscher W., Honack D., White H.S., and Wolf H.H. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23 (1996) 211-223
125. A receptor subtypes. Nature 401 (1999) 796-800
126. + channels in neuronal cells. Eur. J. Pharmacol. 336 (1997) 243-249
127. Rundfeldt C., and Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50 (2000) 1063-1070
128. Rundfeldt C., and Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. 282 (2000) 73-76
129. Sachdeo R., Porter R., Biton V., Rosenfeld W., Alves W., and Nohria V. Dose finding study of retigabine (a novel AED) in patients with epilepsy. Epilepsia 46 Suppl. 8 (2005) 185 (2.280)
130. Sarro G., Ferreri G., Gareri P., Russo E., De Sarro A., Gitto R., and Chimirri A. Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents. Pharmacol. Biochem. Behav. 74 (2003) 595-602
131. + channel sensitivity to the anticonvulsant retigabine. J. Neurosci. 25 (2005) 5051-5060
132. Schmidt D., and Rogawski M.A. New strategies for the identification of drugs to prevent the development or progression of epilepsy. Epilepsy Res. 50 (2002) 71-78
133. Schmutz M., Allgeier H., Jeker A., Klebs K., McLean M.J., Mondadori C., Portet Ch., Vassout A., Wamil A.W., and Meier R. Anticonvulsant profile of CGP 33101 in animals. Epilepsia 34 2 (1993) 122
134. + channels causes epilepsy. Nature 396 (1998) 687-690
135. Shen M., Béguin C., Golbraikh A., Stables J.P., Kohn H., and Tropsha A. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. J. Med. Chem. 47 (2004) 2356-2364
136. Simeone T.A., and McClellan A.M. Felbamate demonstrates subunit selective activity in recombinant GABA-A receptors. Epilepsia 41 Suppl. 7 (2000) 36
137. Sobol E., Bialer M., and Yagen B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. 47 (2004) 4316-4326
138. Sobol E., Yagen B., Winkler I., Britzi M., Gibson D., and Bialer M. Pharmacokinetics and metabolism of a new potent antiepileptic drug 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. Drug Metab. Dispos. 33 (2005) 1538-1546
139. Spiegelstein O., Yagen B., Levy R.H., Finnell R.H., Bennett G.D., Roeder M., Schurig V., and Bialer M. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm. Res. 16 (1999) 1582-1588
140. Stables, J.P., Bertram, E.H., White, H.S., Coulter, D.A., Dichter, M.A., Jacobs, M.P., Löscher, W., Lowenstein, D.H., Moshé, S.L., Noebels, J.L., Davis, M., 2002. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 43, 1410-1420.
141. Stefani A., Calabresi P., Pisani A., Mercuri N.B., Siniscalchi A., and Bernardi G. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J. Pharmacol. Exp. Ther. 277 (1996) 121-127
142. A receptors. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 14439-14444
143. Subramaniam S., Rho J.M., Penix L., Donevan S.D., Fielding R.P., and Rogawski M.A. Felbamate block of the N-methyl-d-aspartate receptor. J. Pharmacol. Exp. Ther. 273 (1995) 878-886
144. + channels from human and rat brain. Eur. J. Pharmacol. 316 (1996) 373-377
145. Takahashi M., Ni J.W., Kawasaki-Yatsugi S., Toya T., Yatsugi S.I., Shimizu-Sasamata M., Koshiya K., Shishikura J.I., Sakamoto S., and Yamaguchi T. YM872, a novel selective α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats. J. Pharmacol. Exp. Ther. 284 (1998) 467-473
146. Tatulian L., and Brown D.A. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J. Physiol. 549 Pt 1 (2003) 57-63
147. Tatulian L., Delmas P., Abogadie F.C., and Brown D.A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. 21 (2001) 5535-5545
148. Thompson C.D., Miller T.A., Barthen M.T., Dieckhaus C.M., Sofia R.D., and Macdonald T.L. The synthesis, in vitro reactivity, and evidence for formation in humans of 5-phenyl-1,3-oxazinane-2,4-dione, a metabolite of felbamate. Drug Metab. Dispos. 28 (2000) 434-439
149. Tober C., Rostock A., Rundfeldt C., and Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. 303 (1996) 163-169
150. Troughton, G.M., Kleckner, N.M., 2005. An Investigation of the subtype-selective antagonism of N-methyl-d-aspartate receptors by new antiepileptic agent, R-2-acetamido-N-benzyl-3-methoxypropionamide, Bates College Thesis Abst.
151. Turski L., Huth A., Sheardown M., McDonald F., Neuhaus R., Schneider H.H., Dirnagl U., Wiegand F., Jacobsen P., and Ottow E. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 10960-10965
152. A receptor complex. Eur. J. Pharmacol. 464 (2003) 95-100
153. V1.5 voltage-gated sodium channel subtypes using a membrane potential sensitive dye and FLIPR. Receptors Channels 10 (2004) 11-23
154. Volosov A., Xiaodong S., Perucca E., Yagen B., Sintov A., and Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol. Ther. 66 (1999) 547-553
155. Walters M.R., Kaste M., Lees K.R., Diener H.C., Hommel M., De Keyser J., Steiner H., and Versavel M. The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc. Dis. 20 (2005) 304-309
156. Watanabe H., Nagata E., Kosakai A., Nakamura M., Yokoyama M., Tanaka K., and Sasai H. Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J. Neurochem. 75 (2000) 28-33
157. White H.S., Schmutz M., Pozza M., Wolf H., Stables J., and Kupferberg H. The anticonvulsant profile and tolerability of rufinamide in mice and rats. Epilepsia 46 Suppl. 8 (2005) 304-306 (3.088)
158. White H.S., Wolf H.H., Swinyard E.A., Skeen G.A., and Sofia R.D. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 33 (1992) 564-572
159. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., and Wolf H.H. General principles discovery and preclinical development of antiepileptic drugs. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott-Raven, Philadelphia 36-48
160. A receptor gene family: new opportunities for drug development. Curr. Opin. Drug Discov. Devel. 6 (2003) 648-657
161. Wickenden, A.D., McNaughton-Smith, G., Roeloffs, R., London, B., Clark, S., Wilson, W.A., Rigdon, G.C., Wagoner, P.K., 2005. ICA-27243: A novel, potent, and selective KCNQ2/Q3 potassium channel activator. Soc. Neurosci. Abst. Prog. No. 153.13.
162. Wickenden A.D., Zou A., Wagoner P.K., and Jegla T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br. J. Pharmacol. 132 (2001) 381-384
163. Winkler I., Blotnik S., Shimshoni J., Yagen B., Devor M., and Bialer M. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol. 146 (2005) 198-208
164. A receptors containing the δ subunit. J. Neurosci. 22 (2002) 1541-1549
165. Wuttke T.V., Seebohm G., Bail S., Maljevic S., and Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol. 67 (2005) 1009-1017
166. Yamaguchi S., Donevan S.D., and Rogawski M.A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15 (1993) 179-184